- |||||||||| alisertib (MLN8237) / Puma
Trial completion, Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Dec 19, 2017 P2, N=72, Completed, Active, not recruiting --> Completed Suspended --> Completed | Trial primary completion date: Feb 2016 --> Aug 2015
- |||||||||| dasatinib / Generic mfg.
Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Oct 13, 2016 P2, N=386, Active, not recruiting, N=30 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Dec 2018 --> Mar 2017 Trial primary completion date: Jun 2015 --> Dec 2016
- |||||||||| Trial completion, Enrollment change: Hippocampal Radiation Exposure and Memory (clinicaltrials.gov) - Jun 23, 2016
P=N/A, N=1, Completed, Trial primary completion date: Jul 2016 --> Dec 2018 Recruiting --> Completed | N=30 --> 1
- |||||||||| Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment change, Trial termination: A Study of Nilotinib in Growing Vestibular Schwannomas (clinicaltrials.gov) - Mar 14, 2016 P2, N=2, Terminated, Active, not recruiting --> Completed N=90 --> 2 | Recruiting --> Terminated; Study PI passed away We had trouble recruiting for the drug arm
- |||||||||| alisertib (MLN8237) / Puma
Enrollment change, Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Oct 7, 2015 P2, N=135, Suspended, Trial primary completion date: Nov 2014 --> Nov 2015 N=59 --> 135 | Trial primary completion date: Aug 2015 --> Feb 2016
- |||||||||| RG4733 / Roche
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Sep 29, 2015 P1, N=22, Completed, N=59 --> 135 | Trial primary completion date: Aug 2015 --> Feb 2016 Active, not recruiting --> Completed | N=34 --> 22 | Trial primary completion date: May 2017 --> Jun 2013
- |||||||||| alisertib (MLN8237) / Puma
Enrollment change, Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Sep 16, 2015 P2, N=59, Suspended, Trial primary completion date: Aug 2015 --> Nov 2014 N=135 --> 59 | Trial primary completion date: Feb 2016 --> Aug 2015
- |||||||||| RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial completion, Enrollment change, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - May 26, 2015 P1b, N=78, Completed, Active, not recruiting --> Completed | N=25 --> 11 Active, not recruiting --> Completed | N=120 --> 78
- |||||||||| dasatinib / Generic mfg.
Enrollment change, Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Dec 19, 2014 P2, N=386, Active, not recruiting, N=61 --> 5 | Active, not recruiting --> Terminated; Lack of accrual N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015
- |||||||||| alisertib (MLN8237) / Puma
Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Dec 17, 2014 P2, N=135, Suspended, Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Jun 2014 Trial primary completion date: Aug 2014 --> Mar 2015
|